Holen Sie sich die Stockscreener-App
17.21
5.13%
0.84
Schlusskurs vom Vortag:
$16.37
Offen:
$16.9
24-Stunden-Volumen:
2.96M
Relative Volume:
1.96
Marktkapitalisierung:
$2.44B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.61M
KGV:
-53.20
EPS:
-0.3235
Netto-Cashflow:
$-45.40M
1W Leistung:
+27.86%
1M Leistung:
+28.15%
6M Leistung:
+41.18%
1J Leistung:
+183.53%
1-Tages-Spanne:
$16.48
$17.61
1-Wochen-Bereich:
$13.52
$17.61
52-Wochen-Spanne:
$5.41
$17.61
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
17.21 | 2.44B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics Inc (TRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trevi Therapeutics Inc (TRVI) Institutional Confidence - TradingKey
Trevi Therapeutics Inc (TRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trevi Therapeutics Inc (TRVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Trevi Therapeutics stock hits all-time high at 16.13 USD By Investing.com - Investing.com Nigeria
Trevi Therapeutics Inc (TRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Trevi Therapeutics Inc (TRVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Trevi Therapeutics Announces Upcoming June and July Event Schedule - Yahoo Finance
Certain Stock Options of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Warrants of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
TRVI Q1 2026 Earnings: Clinical Progress Drives Stock Gains Despite EPS MissEarnings Call Q&A - newsline.com
Trevi Therapeutics Shareholders Approve Stock and Governance Changes - The Globe and Mail
Trevi Therapeutics (TRVI) director receives 35,000-share stock option grant - Stock Titan
Trevi Therapeutics (TRVI) doubles authorized stock, adds 8,000,000-plan shares - Stock Titan
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) director receives 35K nonstatutory option grant - Stock Titan
Director at Trevi Therapeutics (NASDAQ: TRVI) awarded 35,000 stock options - Stock Titan
Director at Trevi Therapeutics (TRVI) receives 35,000 stock options award - Stock Titan
Trevi Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. - AOL.com
TRVI: All proposals passed, including share increase and director election, with no shareholder questions - TradingView
Pivotal bioVenture Partners Increases Trevi Therapeutics Holdings by 296,944 Shares in Q1 2026News and Statistics - IndexBox
Trevi Therapeutics stock hits 52-week low at 13.68 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits 52-week low at 13.68 USD - Investing.com
TRVI Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineProfit Growth Outlook - newsline.com
Trevi Therapeutics (TRVI) Holds Near Resistance After Modest GainNew Highs New Lows - The Legal Advocate
Trevi Therapeutics (TRVI) Shows Potential as Shares Climb Over 2%OBV Divergence - thelegaladvocate.com
Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation - MSN
Clear Street Maintains Trevi Therapeutics (TRVI) Buy Recommendation - MSN
TRVI Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss, Shares Edge HigherRevenue Inflection Point - thelegaladvocate.com
Trevi Therapeutics Q1 2026 Earnings: Narrowing Losses but Trial Failures Weigh on SentimentPost-Announcement Reaction - The Legal Advocate
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Quantisnow
TRVI Reiterated by Needham -- Price Target Maintained at $23 - GuruFocus
Trevi Therapeutics (TRVI) Q1 2026 Disappoints — EPS $-0.09 Below $-0.08 ViewsSpecial Dividend Alert - newsline.com
Trevi Therapeutics stock (US89357P1049): short interest remains high as Wall Street targets signal u - AD HOC NEWS
Trevi Therapeutics (TRVI) Q1 2026 Earnings: Miss Sparks ConcernProfit Margin Analysis - thelegaladvocate.com
Trevi Therapeutics maps Haduvio chronic cough push, sees cash runway into 2030 - MSN
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - GuruFocus
Trevi Therapeutics, Inc. (TRVI) Analyst/Investor DaySlideshow (NASDAQ:TRVI) 2026-05-15 - Seeking Alpha
Trevi Therapeutics, Inc.Common Stock (Nasdaq:TRVI) Stock Quote - FinancialContent
Trevi Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
TradingKey - TradingKey
Revenue per share of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
TRVI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Nan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
F m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Comerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 - sharewise.com
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):